• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

A Review of the Regulatory Hurdles Remaining for the CVS Aetna Acquisition

Aetna's additive effects on CVS's earnings might be front and center, but it isn't fully actualized just yet.
By KEVIN CURRAN May 01, 2019 | 02:42 PM EDT
Stocks quotes in this article: CVS

As CVS Health (CVS) continues to tout its Aetna acquisition as a big part of the company's future and as an additive aspect to results, it's important to note the remaining hoops left to jump through.

While the deal was approved in the fall, the initial green light was not a final say.

As those following the deal will recall, U.S. District Judge Richard Leon asked to hear from select witnesses before deciding whether or not to to sign off on the acquisition sent through by the Department of Justice.

The main sticking point is whether or not the deal would violate the Antitrust Procedures and Penalties Act, or Tunney Act, as has been argued by medical associations and consumer protection agencies decrying the acquisition. At least seven witnesses have come forward, according to court filings, to present arguments about the harms to competition and Medicare coverage such a deal would present.

CVS sought to quickly quell the arguments, responding in a motion to exclude the testimony of the amici in a court filing last week on the grounds that the Tunney act is not applicable.

"Such evidence and arguments are irrelevant to the proposed Final Judgment and threaten to turn this Tunney Act proceeding into a forum for airing competitors' grievances about the CVS-Aetna merger and about the healthcare industry more generally," CVS argued. "That is not what Tunney Act review is for."

"In light of Amici's witness list submissions, CVS also respectfully suggests that the Court should exercise its discretion to dispense altogether with an evidentiary hearing with live witness testimony," CVS' argument added. "Amici's submissions demonstrate that such a hearing is unnecessary in light of the considerable record already before the Court, and Amici's planned presentations, consisting almost exclusively of unreliable competitor testimony on issues that are not relevant to the Court's Tunney Act determination, will add little, if anything, of value."

The DOJ was inclined to agree, filing its own response to the challenge on Monday.

"Much of the testimony proposed by the American Medical Association, AIDS Healthcare Foundation, and Consumer Action and U.S. PIRG is beyond the statutory
scope of Tunney Act review and is otherwise inadmissible in an evidentiary hearing of the kind currently proposed," a statement reads. "Specifically, the proposed testimony relating to alleged antitrust violations that amici believe the United States should have included in the Complaint is beyond the scope of the public-interest inquiry before the Court and is therefore irrelevant. Consequently, it should be excluded. Much of the opinion testimony offered by amici is also inadmissible or unsupported. It, too, should be excluded."

As such, the leaner testimony is unlikely to significantly impact the deal.

"While we believe a full on rejection of the merger to be highly unlikely and question how much, if any, influence Judge Leon has to contradict the Justice Department's ruling, we think it is a scenario worth considering as it allows to better quantify the result of a worst-case outcome," TheStreet's Action Alerts PLUS team advised. "Should this be the case, we would essentially be back at step one, with CVS being strictly a pharmacy, PBM, retail operation without the added synergies and verticals provided by Aetna."

Considering Aetna was at the forefront of the earnings call on Wednesday, that scenario only looks worse.

On the bright side, all of the debt amassed by CVS in the blockbuster deal would be shed and CVS would be a low-multiple stock with a strong balance sheet, especially considering a stock slide would be anticipated if such a deal would fall through. Furthermore, retail operations in the domestic-focused company appear to be quite strong. In total, the company would recoup $45 billion plus an $8 billion breakup fee from Aetna, a recall of nearly 275 million shares, and regain some of the cash spent on the deal. The risk of integrating Aetna would also evaporate as an overhang.

In the end, the worst case is really not the worst thing that could happen, unlikely as it is.

"While we are aware of the overhang on the stock resulting from Judge Leon's insistence on hearing live testimony, we do not believe it poses any additional risk to the downside and continue to view shares as deeply undervalued regardless of the outcome," Action Alerts reasoned. "We therefore reiterate our One ["Buy"] rating and will continue to look for material weakness as a means to reduce basis and increase our position as we continue to be of the mind that the Aetna integration will take place and the longer-term outlook of the company will be much brighter as a result."

For the team's full investment outlook on their CVS position after the earnings release, click here.

(CVS Health is a holding in Jim Cramer's Action Alerts PLUS Charitable Trust Portfolio. Want to be alerted before Cramer buys or sells this stock? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

Action Alerts PLUS, which Cramer manages as a charitable trust, is long CVS.

TAGS: Law | Mergers and Acquisitions | Regulation | Litigation | Earnings | Investing | Stocks | Healthcare | Pharmaceuticals | Stock of the Day

More from Stocks

Lopsided Market Returns

James "Rev Shark" DePorre
Jun 5, 2023 4:22 PM EDT

Despite the intraday reversal in Apple, Microsoft, Alphabet, Amazon, and Tesla, all helped the Nasdaq 100 outperform the other indexes as the small caps disappointed.

How to Trade MongoDB After Its Huge Upside Move

Bruce Kamich
Jun 5, 2023 1:45 PM EDT

Let's check out the charts and indicators for clues.

This Value Portfolio of Lovable Losers Is Down But Not Out

Jonathan Heller
Jun 5, 2023 1:10 PM EDT

With about six months to go, anything can happen for the 2023 Tax Loss Selling Recovery Portfolio.

Friday's Cheer Turns to Monday Drear

James "Rev Shark" DePorre
Jun 5, 2023 11:35 AM EDT

Even the bulls will likely agree that this market needs better participation and breadth.

As Palo Alto Networks Joins the S&P 500, Here's How to Play the Stock

Stephen Guilfoyle
Jun 5, 2023 11:24 AM EDT

This 'best-in-class' cybersecurity name was already hot, before the news.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:51 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Adjusting Your Trading Approach to Shifting Market...
  • 06:54 PM EDT CHRIS VERSACE

    AAP Podcast: A Tongue -- and a Market -- Twister: 'Get a Debt Deal Done'

    Listen in as the Action Alerts PLUS Podcast tackle...
  • 12:07 PM EDT STEPHEN GUILFOYLE

    Selling Some of This Surging AI-Related Stock

    This isn't the only name in the Stocks Under $10 p...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login